Pharmaceutical Substances - Version 4.4
The version 4.4 of Pharmaceutical Substances was launched in May 2018.
Pharmaceutical Substances 4.4 contains 14 new APIs and a total of 39,916 structures, 12,005 reactions, and 2,688 active pharmaceutical ingredients.
• Baloxavir Marboxil
“This spring release of Pharmaceutical Substances is focused on 14 new active pharmaceutical ingredients (APIs) and includes many drug products that have an innovative mechanism of action together with an FDA breakthrough status.
Among them are the anticancer drugs Abemaciclib (CDK4/6 inhibitor from E. Lilly), Acalabrutinib (BTK inhibitor from AstraZeneca), Copanlisib (pan-PI3K-inhibitor from Bayer) and the most recently approved Apalutamide (Antiandrogen from Janssen Biotech).
Accelerated approval was also received by the new antimicrobial Benznidazole (Chemo Research).
Further tremendous progress has been achieved by modern and more efficacious antivirals: With the new Hepatitis C Virus (HCV) protease inhibitor Voxilaprevir (Gilead Sciences) in a fixed combination with Sofosbuvir and Velpatasvir an all-oral treatment against HCV infections with outstanding cure rates is now available. In addition, Abbvie launched a fixed combination of Glecaprevir and Pibrentasvir against HCV being similarly efficacious. Furthermore, this update covers Letermovir, a Cytalomegalovirus DNA terminase inhibitor developed by Merck & Co. for infection prevention after bone marrow transplant and the endonuclease inhibitor Baloxavir Marboxil (Shionogi) for treatment against influenza type A and B virus infections. The new drug was recently first approved in Japan and is characterized by only taking one single oral dose in order to suppress virus replication!
Additionally, you will find new entries such as the once-weekly administered antidiabetic GLP-1 -inhibitor Semaglutide (Novo Nordisk), Macimorelin, Ioversol and Mirabegron in this latest release.”
Prof. Bernhard Kutscher
Thieme Chemistry Marketing Phone:+49-711-8931-771 Fax:+49-711-8931-777 E-Mail